Anixa Biosciences Inc

Nasdaq:ANIX

Pharmaceutical Preparations·SAN JOSE, CA

CEO

Kumar Amit

CFO

Catelani Michael

Summary Financials

Revenue

$210,000

+0.0% YoY

FY 2024

Adj. EBITDA

-$13.8M

-6565.6% margin

FY 2025

Net Income

-$12.6M

-5978.1% margin

FY 2025

EPS (Diluted)

-$0.39

FY 2025

Stock Price

$2.99

+4.9%

2026-03-09

52W Range

$2.33 – $5.46

P/E Ratio

-7.7x

Market Cap

$100.2M

Cash

$1.3M

FY 2025

Total Debt

$750,946

FY 2015

Net Cash

$520,054

FY 2015

Enterprise Value

$99.7M

Debt / EBITDA

0.0x

FY 2024

EV / EBITDA

-7.2x

Employees

—

Revenue

$210,000

+0.0% YoY

FY 2024

Adj. EBITDA

-$13.8M

-6565.6% margin

FY 2025

Net Income

-$12.6M

-5978.1% margin

FY 2025

EPS (Diluted)

-$0.39

FY 2025

Stock Price

$2.99

+4.9%

2026-03-09

52W Range

$2.33 – $5.46

P/E Ratio

-7.7x

Market Cap

$100.2M

Cash

$1.3M

FY 2025

Total Debt

$750,946

FY 2015

Net Cash

$520,054

FY 2015

Enterprise Value

$99.7M

Debt / EBITDA

0.0x

FY 2024

EV / EBITDA

-7.2x

Employees

—